Schleifer, Yancopoulos And The $36 Billion Friendship
Executive Summary
In 1988 Len Schleifer took a talented scientist, George Yancopoulos, out to dinner to persuade the immunologist to join his newly formed company. Thirty years, six drug approvals and many arguments later, pharma’s most famous friendship is now looking to change the way allergies are treated.
You may also be interested in...
Investment And Acquisition In Rare Diseases
In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.
Moving The Needle In Rare Disease: UCB’s gMG Strategy
Launching a novel drug into a new market is tough. UCB’s Kimberly Moran, talked to In Vivo about how being both patient and digital first gives the company a competitive commercial advantage in an increasingly growing market.
Win Big Or Lose Big: The Impact Of The Unified Patent Court
Decades after it was first mentioned, the updated European patent system – which includes the Unitary Patent and the Unified Patent Court – has finally materialized. What impact will this have on originator and generic pharma?